Business Context and Reporting Period
Company: SELLAS Life Sciences Group, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 4, 2024
Event: Entry into a Material Definitive Agreement regarding a private placement offering of securities.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key metrics include:
- Gross Proceeds: Approximately $9.0 million (before fees and expenses).
- Securities Issued:
- 10,130,000 shares of Common Stock.
- 1,870,000 Pre-Funded Warrants (exercisable at $0.0001).
- Common Warrants to purchase up to 12,000,000 shares of Common Stock.
- Offering Price: $0.75 per share of Common Stock (plus warrant); $0.7499 per Pre-Funded Warrant (plus warrant).
- Placement Agent Fee: 7.0% of gross proceeds paid to A.G.P./Alliance Global Partners.
- Legal Expense Cap: Reimbursement of legal fees up to $60,000.
- Share Count Impact: Outstanding shares increased from 32,132,890 to 42,262,890 immediately following the offering (excluding warrant exercises).
Material Changes and Modifications
The filing reports the following material changes resulting from the transaction:
- Capital Structure: Significant dilution of existing shareholders due to the issuance of over 12 million new shares and warrants.
- Warrant Modifications:
- Exercise price reduction for 3,863,851 warrants issued in April 2022 to $0.75.
- Exercise price reduction for 3,652,300 warrants issued in November 2023 to $0.75.
- Extension of the termination date for both the April 2022 and November 2023 warrants to January 8, 2029.
- Ownership Caps: Implementation of beneficial ownership limits (4.99% or 9.99%) for purchasers to prevent excessive concentration of ownership.
Outlook, Restrictions, and Risks
- Issuance Restrictions: The Company is restricted from issuing or selling Common Stock or Common Stock Equivalents for 60 days following the closing of the Offering.
- Warrant Terms: Common Warrants are immediately exercisable at $0.75 per share and expire five years from the initial exercise date.
- Registration: Securities were offered pursuant to an effective Form S-3 registration statement filed in April 2021.
- Legal Opinion: An opinion regarding the legality of the issuance was provided by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Investor Verification Checklist
- Verify the net proceeds after deducting the 7% placement fee and legal expenses.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification terms.
- Assess the impact of the 12,000,000 new Common Warrants on future dilution if exercised.
- Confirm the current cash position of the company to understand the runway provided by the $9.0 million gross proceeds.
- Check for any subsequent filings regarding the exercise of Pre-Funded Warrants, which would further increase the share count.